Company news
Merck & Company, Inc. (NYSE:MRK) news
Every Merck & Company, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
February 11, 2026
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
February 11, 2026
Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform
February 10, 2026
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
February 5, 2026
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
February 3, 2026
Snowflake Makes Enterprise Data AI-Ready With Snowflake Postgres and Advanced Innovations for Open Data Interoperability
February 3, 2026
Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population
January 28, 2026
Merck Announces Second-Quarter 2026 Dividend
January 27, 2026
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
January 20, 2026
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
January 19, 2026
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board
January 16, 2026
TetraScience Appoints Matt Studney as Chief Customer Officer, Signaling Industry Shift Toward Platform-Based Scientific AI
January 14, 2026
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
January 11, 2026
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
January 7, 2026
Merck to Complete Acquisition of Cidara Therapeutics
January 7, 2026
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
January 7, 2026
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
December 19, 2025
Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes
December 17, 2025
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
December 17, 2025
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
December 16, 2025
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
December 12, 2025
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
December 9, 2025
Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program
December 8, 2025
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
December 5, 2025
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
December 4, 2025
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
December 1, 2025
Merck to Participate in the Citi 2025 Global Healthcare Conference
November 26, 2025
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
November 26, 2025
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
November 24, 2025
Merck Recommends Rejection of Tutanota’s "Mini-Tender" Offer
November 21, 2025
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
November 21, 2025
VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future
November 20, 2025
Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)
November 20, 2025
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
November 19, 2025
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
November 19, 2025
Merck Announces First-Quarter 2026 Dividend
November 18, 2025
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
November 18, 2025
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
November 14, 2025
Merck to Participate in the Jefferies Global Healthcare Conference in London
November 13, 2025
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
November 9, 2025
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
November 8, 2025
Codexis Reports Third Quarter 2025 Financial Results
November 6, 2025
Alliance for Building Better Medicine and the Virginia Innovation Partnership Celebrate $120 Million Investment from AstraZeneca, Eli Lilly, and Merck to Advance Virginia's Advanced Pharmaceutical Manufacturing Workforce
November 5, 2025
Quebec Expands Public Funding for CAPVAXIVE®
November 5, 2025
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
November 4, 2025
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
November 4, 2025
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
November 3, 2025
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
October 31, 2025
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
October 30, 2025